GSK
GSK plc
Price Chart
Latest Quote
$50.98
-0.12 (-0.23%)
Current Price
| Previous Close | $51.10 |
| Open | $50.80 |
| Day High | $51.25 |
| Day Low | $50.63 |
| Volume | 4,316,287 |
Stock Information
Note: Financial values converted from GBP to USD
| Quarterly Dividend / Yield | $1.82 / 3.55% |
| Shares Outstanding | 2.00B |
| Quarterly Dividend Yield | 3.55% |
| Quarterly Dividend | $1.82 |
| Total Debt | $24.35B |
| Cash Equivalents | $4.13B |
| Revenue | $44.20B |
| Net Income | $6.42B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $102.14B |
| P/E Ratio | 16.08 |
| EPS (TTM) | $3.17 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $117.10B |
| Sales | $44.20B |
| Income | $6.42B |
| Book/sh | $11.80 |
| Cash/sh | $1.55 |
| Employees | 67K |
Financial Ratios
| Quick Ratio | 0.52 |
| Current Ratio | 0.81 |
| Debt/Eq | 106.50 |
| EPS Growth TTM | -69.90% |
Returns & Margins
| ROA | 10.01% |
| ROE | 33.38% |
| Gross Margin | 73.49% |
| Operating Margin | 30.94% |
| Profit Margin | 14.52% |
Ownership
| Insider Ownership | 0.06% |
| Institutional Ownership | 17.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.33 |
| PEG | 6.16 |
| P/S | 3.08 |
| P/B | 4.32 |
Analyst Data
| Recommendation | buy |
| Target Price | $60.51 |
Technical Indicators
| SMA20 | $48.47 |
| SMA50 | $49.61 |
| SMA200 | $51.74 |
| RSI | 72.55 |
| ATR | 1.0439 |
| Shares Float | 1.94B |
| Short Float | 0.74% |
| Short Ratio | 4.77 |
| Volatility | 0.28 |
| Rel Volume | 0.73 |
Performance History
| Week | +0.69% |
| Month | +2.58% |
| Quarter | -3.34% |
| 6 Months | -4.70% |
| YTD | +5.44% |
| Year | +22.08% |
| 3 Years | +61.04% |
| 5 Years | +59.34% |
| 10 Years | +101.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $50.98 | 4,316,287 |
| 2026-10-26 | $51.10 | 3,609,400 |
| 2026-10-23 | $50.75 | 3,178,800 |
| 2026-10-22 | $51.21 | 4,283,400 |
| 2026-10-21 | $50.02 | 3,614,100 |
| 2026-10-20 | $50.63 | 5,597,200 |
| 2026-10-19 | $49.46 | 5,372,900 |
| 2026-10-16 | $49.51 | 6,923,500 |
| 2026-10-15 | $49.02 | 6,141,500 |
| 2026-10-14 | $47.87 | 7,087,500 |
| 2026-10-13 | $46.27 | 5,756,400 |
| 2026-10-12 | $46.92 | 10,345,400 |
| 2026-10-09 | $46.50 | 8,542,700 |
| 2026-10-08 | $46.54 | 7,730,500 |
| 2026-10-07 | $47.02 | 5,852,600 |
| 2026-10-06 | $46.60 | 6,806,400 |
| 2026-10-05 | $46.55 | 3,480,400 |
| 2026-10-02 | $47.03 | 5,385,700 |
| 2026-10-01 | $47.18 | 7,896,400 |
| 2026-09-30 | $48.17 | 5,852,300 |
| 2026-09-29 | $49.35 | 2,892,700 |
| 2026-09-28 | $49.70 | 3,586,600 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
đ° Latest News
No news articles available at the moment. Check back later for updates on GSK.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $12,019,141,621 | $12,060,462,835 | $11,416,651,656 | $12,734,931,690 |
| Cost Of Revenue | $12,019,141,621 | $12,060,462,835 | $11,416,651,656 | $12,734,931,690 |
| Total Revenue | $43,543,229,381 | $41,822,400,742 | $40,425,477,107 | $39,087,202,938 |
| Operating Revenue | $43,543,229,381 | $41,822,400,742 | $40,425,477,107 | $39,087,202,938 |
| Expenses | ||||
| Interest Expense | $915,731,429 | $853,083,136 | $966,383,240 | $1,101,010,422 |
| Total Expenses | $32,429,155,650 | $34,435,233,962 | $30,635,015,179 | $30,117,833,528 |
| Net Non Operating Interest Income Expense | $-843,752,539 | $-803,764,267 | $-979,712,664 | $-1,101,010,422 |
| Total Other Finance Cost | $2,665,885 | $30,657,675 | $77,310,659 | $41,321,214 |
| Interest Expense Non Operating | $915,731,429 | $853,083,136 | $966,383,240 | $1,101,010,422 |
| Operating Expense | $20,410,014,029 | $22,374,771,126 | $19,218,363,523 | $17,382,901,838 |
| General And Administrative Expense | $12,113,780,531 | $14,682,360,536 | $12,509,664,424 | $11,159,393,773 |
| Rent Expense Supplemental | - | $39,988,272 | $35,989,445 | $22,660,021 |
| Other Operating Expenses | - | $11,996,482 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $7,619,098,758 | $3,432,326,680 | $6,568,740,147 | $5,673,002,854 |
| Net Interest Income | $-843,752,539 | $-803,764,267 | $-979,712,664 | $-1,101,010,422 |
| Interest Income | $74,644,774 | $79,976,544 | $63,981,235 | $41,321,214 |
| Normalized Income | $7,964,562,452 | $5,082,886,214 | $7,199,721,756 | $5,991,045,577 |
| Net Income From Continuing And Discontinued Operation | $7,619,098,758 | $3,432,326,680 | $6,568,740,147 | $19,935,486,534 |
| Total Operating Income As Reported | $10,572,899,117 | $5,359,761,390 | $8,990,696,488 | $8,574,818,459 |
| Net Income Common Stockholders | $7,619,098,758 | $3,432,326,680 | $6,568,740,147 | $19,935,486,534 |
| Net Income | $7,619,098,758 | $3,432,326,680 | $6,568,740,147 | $19,935,486,534 |
| Net Income Including Noncontrolling Interests | $8,382,874,754 | $3,933,513,022 | $7,075,258,259 | $20,821,893,230 |
| Net Income Continuous Operations | $8,382,874,754 | $3,933,513,022 | $7,075,258,259 | $6,559,409,550 |
| Pretax Income | $9,865,106,702 | $4,634,640,725 | $8,082,962,714 | $7,501,799,827 |
| Special Income Charges | $-1,083,682,171 | $-1,643,517,979 | $-938,391,450 | $-1,640,852,094 |
| Interest Income Non Operating | $74,644,774 | $79,976,544 | $63,981,235 | $41,321,214 |
| Operating Income | $11,114,073,731 | $7,387,166,781 | $9,790,461,928 | $8,969,369,410 |
| Gross Profit | $31,524,087,760 | $29,761,937,907 | $29,008,825,451 | $26,352,271,248 |
| Net Income Discontinuous Operations | - | $0 | $0 | $14,262,483,680 |
| Per Share | ||||
| Diluted EPS | $3.70 | $1.66 | $3.20 | $9.76 |
| Basic EPS | $3.76 | $1.68 | $3.24 | $9.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $-61,083,738 | $-294,203,428 | $-90,140,230 | $-45,850,553 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $14,271,814,277 | $10,832,822,885 | $12,828,237,658 | $11,828,530,858 |
| Total Unusual Items | $-406,547,432 | $-1,944,762,962 | $-721,121,838 | $-363,893,275 |
| Total Unusual Items Excluding Goodwill | $-406,547,432 | $-1,944,762,962 | $-721,121,838 | $-363,893,275 |
| Reconciled Depreciation | $3,084,428,714 | $3,400,336,062 | $3,057,769,866 | $2,861,827,333 |
| EBITDA (Bullshit earnings) | $13,865,266,845 | $8,888,059,923 | $12,107,115,819 | $11,464,637,582 |
| EBIT | $10,780,838,131 | $5,487,723,861 | $9,049,345,954 | $8,602,810,250 |
| Diluted Average Shares | $2,743,861,930 | $2,760,523,710 | $2,739,863,103 | $2,721,868,381 |
| Basic Average Shares | $2,699,874,831 | $2,717,203,082 | $2,700,541,302 | $2,683,213,051 |
| Diluted NI Availto Com Stockholders | $7,619,098,758 | $3,432,326,680 | $6,568,740,147 | $19,935,486,534 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Minority Interests | $-763,775,995 | $-501,186,342 | $-506,518,112 | $-886,406,696 |
| Tax Provision | $1,482,231,949 | $701,127,702 | $1,007,704,454 | $942,390,277 |
| Other Special Charges | $309,242,637 | $-690,464,163 | $-115,965,989 | $-501,186,342 |
| Restructuring And Mergern Acquisition | $774,439,534 | $2,333,982,142 | $1,054,357,438 | $2,142,038,437 |
| Research And Development | $10,030,391,560 | $8,532,164,302 | $8,294,900,555 | $7,315,187,891 |
| Selling General And Administration | $12,113,780,531 | $14,682,360,536 | $12,509,664,424 | $11,159,393,773 |
Fetched: 2026-10-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-9,849,111,394 | $-11,764,549,622 | $-10,972,781,837 | $-14,350,457,878 |
| Total Assets | $81,466,773,603 | $79,260,753,931 | $78,650,266,312 | $80,171,153,590 |
| Total Non Current Assets | $58,126,952,179 | $56,604,731,958 | $53,798,888,206 | $52,487,272,885 |
| Non Current Deferred Taxes Assets | $8,690,784,448 | $9,006,691,797 | $8,062,968,578 | $7,541,788,099 |
| Financial Assets | $0 | $1,332,942 | $0 | $0 |
| Investmentin Financial Assets | $1,403,588,347 | $1,514,222,566 | $1,551,544,954 | $2,000,746,542 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $350,563,851 | $383,887,411 | $298,579,098 | $435,872,165 |
| Goodwill And Other Intangible Assets | $31,678,709,078 | $29,987,205,173 | $28,763,564,050 | $28,476,981,434 |
| Other Intangible Assets | $22,324,119,315 | $20,680,601,336 | $19,684,893,363 | $19,085,069,283 |
| Current Assets | $23,339,821,424 | $22,656,021,973 | $24,851,378,106 | $27,683,880,706 |
| Hedging Assets Current | $161,286,030 | $145,290,722 | $173,282,512 | $253,259,056 |
| Assets Held For Sale Current | $399,882,720 | $3,998,827 | $101,303,622 | $130,628,355 |
| Restricted Cash | $329,236,773 | $235,930,805 | $253,259,056 | $266,588,480 |
| Prepaid Assets | $513,182,824 | $519,847,536 | $473,194,552 | $457,199,243 |
| Inventory | $7,896,350,778 | $7,556,450,466 | $7,328,517,315 | $6,859,321,590 |
| Other Receivables | $882,407,869 | $581,162,886 | $746,447,744 | $1,021,033,878 |
| Taxes Receivable | $1,065,020,978 | $1,247,634,086 | $1,250,299,971 | $1,195,649,333 |
| Accounts Receivable | $7,881,688,411 | $7,415,158,571 | $7,871,024,872 | $7,267,201,965 |
| Gross Accounts Receivable | $7,881,688,411 | $7,415,158,571 | $7,984,324,976 | $7,388,499,723 |
| Cash Cash Equivalents And Short Term Investments | $4,210,765,042 | $4,950,548,074 | $6,654,048,461 | $10,232,998,805 |
| Cash And Cash Equivalents | $4,198,768,560 | $4,922,556,283 | $3,660,259,830 | $4,695,956,075 |
| Allowance For Doubtful Accounts Receivable | - | $-131,961,298 | $-113,300,104 | $-121,297,758 |
| Debt | ||||
| Net Debt | $18,314,628,576 | $16,249,900,798 | $18,747,834,856 | $21,934,900,134 |
| Total Debt | $23,619,739,328 | $22,641,359,606 | $24,016,956,163 | $27,974,462,149 |
| Long Term Debt And Capital Lease Obligation | $19,604,916,819 | $19,510,277,909 | $20,267,389,192 | $22,706,673,784 |
| Long Term Debt | $18,681,187,736 | $18,265,309,707 | $18,866,466,730 | $21,585,669,226 |
| Current Debt And Capital Lease Obligation | $4,014,822,509 | $3,131,081,698 | $3,749,566,971 | $5,267,788,365 |
| Current Debt | $3,832,209,400 | $2,907,147,374 | $3,541,627,957 | $5,045,186,984 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $60,198,344,669 | $61,817,869,685 | $61,595,268,304 | $66,713,767,120 |
| Total Non Current Liabilities Net Minority Interest | $31,685,373,790 | $32,897,018,432 | $33,512,837,821 | $36,309,350,976 |
| Other Non Current Liabilities | $7,177,894,824 | $8,141,612,179 | $7,476,473,922 | $7,703,074,130 |
| Derivative Product Liabilities | $89,307,141 | $0 | - | $0 |
| Tradeand Other Payables Non Current | $1,194,316,390 | $1,238,303,490 | $1,231,638,778 | $1,242,302,317 |
| Non Current Deferred Taxes Liabilities | $387,886,238 | $509,183,997 | $414,545,086 | $385,220,354 |
| Current Liabilities | $28,512,970,878 | $28,920,851,253 | $28,082,430,483 | $30,404,416,144 |
| Other Current Liabilities | $1,796,806,355 | $1,562,208,493 | $1,403,588,347 | $1,718,162,754 |
| Payables | $5,959,585,470 | $6,111,540,904 | $6,082,216,171 | $6,338,141,112 |
| Other Payable | $583,828,771 | $559,835,808 | $461,198,070 | $557,169,923 |
| Total Tax Payable | $663,805,315 | $937,058,507 | $666,471,200 | $627,815,870 |
| Accounts Payable | $4,711,951,384 | $4,614,646,589 | $4,954,546,901 | $5,153,155,318 |
| Equity | ||||
| Common Stock Equity | $21,829,597,685 | $18,222,655,550 | $17,790,782,213 | $14,126,523,555 |
| Total Equity Gross Minority Interest | $21,268,428,934 | $17,442,884,246 | $17,054,998,008 | $13,457,386,470 |
| Stockholders Equity | $21,829,597,685 | $18,222,655,550 | $17,790,782,213 | $14,126,523,555 |
| Other Equity Interest | $-375,889,757 | $-529,178,133 | $-383,887,411 | $-470,528,667 |
| Retained Earnings | $13,608,008,962 | $10,391,618,950 | $9,649,170,034 | $5,815,627,691 |
| Long Term Equity Investment | $118,631,874 | $127,962,470 | $73,311,832 | $98,637,738 |
| Other | ||||
| Treasury Shares Number | $403,741,194 | $311,222,671 | $341,080,454 | $289,414,799 |
| Ordinary Shares Number | $5,348,498,456 | $5,439,495,703 | $5,406,761,762 | $5,457,357,541 |
| Share Issued | $5,752,239,650 | $5,750,718,374 | $5,747,842,216 | $5,746,772,340 |
| Tangible Book Value | $-9,849,111,394 | $-11,764,549,622 | $-10,972,781,837 | $-14,350,457,878 |
| Invested Capital | $44,342,994,821 | $39,395,112,632 | $40,198,876,899 | $40,757,379,765 |
| Working Capital | $-5,173,149,454 | $-6,264,829,280 | $-3,231,052,378 | $-2,720,535,438 |
| Capital Lease Obligations | $1,106,342,192 | $1,468,902,525 | $1,608,861,477 | $1,343,605,939 |
| Total Capitalization | $40,510,785,421 | $36,487,965,258 | $36,657,248,942 | $35,712,192,781 |
| Minority Interest | $-561,168,750 | $-779,771,304 | $-735,784,205 | $-669,137,085 |
| Additional Paid In Capital | $4,662,632,515 | $4,629,308,955 | $4,599,984,222 | $4,585,321,856 |
| Capital Stock | $1,798,139,298 | $1,796,806,355 | $1,796,806,355 | $1,795,473,413 |
| Common Stock | $1,798,139,298 | $1,796,806,355 | $1,796,806,355 | $1,795,473,413 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,248,673,829 | $2,484,604,634 | $3,119,085,216 | $3,437,658,450 |
| Non Current Accrued Expenses | $7,997,654 | $7,997,654 | $5,331,770 | $14,662,366 |
| Non Current Deferred Revenue | $161,286,030 | $219,935,496 | $338,567,370 | $110,634,219 |
| Long Term Capital Lease Obligation | $923,729,083 | $1,244,968,202 | $1,400,922,462 | $1,121,004,558 |
| Long Term Provisions | $813,094,864 | $785,103,074 | $659,806,488 | $709,125,357 |
| Current Capital Lease Obligation | $182,613,109 | $223,934,323 | $207,939,014 | $222,601,381 |
| Pensionand Other Post Retirement Benefit Plans Current | $183,946,051 | $166,617,800 | $167,950,742 | $167,950,742 |
| Current Provisions | $1,250,299,971 | $2,593,905,910 | $991,709,146 | $869,078,445 |
| Defined Pension Benefit | $1,486,230,776 | $1,196,982,275 | $845,085,482 | $305,243,810 |
| Available For Sale Securities | $1,053,024,496 | $1,130,335,155 | $1,252,965,856 | $1,564,874,378 |
| Investmentsin Joint Venturesat Cost | $0 | $0 | $0 | $13,329,424 |
| Investmentsin Associatesat Cost | $118,631,874 | $127,962,470 | $73,311,832 | $85,308,314 |
| Goodwill | $9,354,589,763 | $9,306,603,837 | $9,078,670,686 | $9,391,912,150 |
| Net PPE | $13,393,405,235 | $13,426,728,795 | $13,272,107,477 | $12,822,905,888 |
| Accumulated Depreciation | $-14,518,408,621 | $-13,973,235,179 | $-13,674,656,082 | $-14,019,888,163 |
| Gross PPE | $27,911,813,856 | $27,399,963,974 | $26,946,763,558 | $26,842,794,051 |
| Construction In Progress | $3,347,018,366 | $3,092,426,368 | $2,825,837,888 | $2,465,943,440 |
| Other Properties | $7,997,654 | $10,663,539 | $5,331,770 | $7,997,654 |
| Machinery Furniture Equipment | $15,642,079,064 | $14,951,614,901 | $14,510,410,966 | $14,759,671,195 |
| Buildings And Improvements | $707,792,414 | $847,751,366 | $1,001,039,742 | $747,780,686 |
| Land And Improvements | $8,206,926,357 | $8,497,507,800 | $8,604,143,192 | $8,861,401,075 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,155,367,861 | $2,166,031,400 | $1,939,431,192 | $1,711,498,042 |
| Work In Process | $4,930,553,938 | $3,576,284,459 | $3,264,375,938 | $3,047,106,326 |
| Raw Materials | $810,428,979 | $1,814,134,606 | $2,124,710,186 | $2,100,717,222 |
| Other Short Term Investments | $11,996,482 | $27,991,790 | $2,993,788,630 | $5,537,042,730 |
Fetched: 2026-10-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $6,339,474,054 | $4,761,270,253 | $5,896,937,178 | $6,857,988,648 |
| Operating Activities | ||||
| Operating Cash Flow | $10,318,307,118 | $8,736,104,490 | $9,021,354,163 | $9,867,772,587 |
| Investing Activities | ||||
| Capital Expenditure | $-3,978,833,064 | $-3,974,834,237 | $-3,124,416,986 | $-3,009,783,939 |
| Investing Cash Flow | $-5,642,345,179 | $-1,638,186,210 | $-2,126,043,128 | $-11,692,570,733 |
| Net Other Investing Changes | - | $-1,332,942 | - | $-5,053,184,638 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,835,461,685 | $0 | $0 | - |
| Issuance Of Capital Stock | $19,994,136 | $26,658,848 | $13,329,424 | $33,323,560 |
| Financing Cash Flow | $-4,911,892,744 | $-6,299,485,782 | $-7,519,128,078 | $1,097,011,595 |
| Net Other Financing Charges | $61,315,350 | $183,946,051 | $454,533,358 | $13,939,911,619 |
| Cash Dividends Paid | $-3,417,664,314 | $-3,257,711,226 | $-2,995,121,573 | $-4,621,311,301 |
| Common Stock Dividend Paid | $-3,417,664,314 | $-3,257,711,226 | $-2,995,121,573 | $-4,621,311,301 |
| Net Common Stock Issuance | $-1,815,467,549 | $26,658,848 | $13,329,424 | $33,323,560 |
| Common Stock Issuance | $19,994,136 | $26,658,848 | $13,329,424 | $33,323,560 |
| Dividends Received Cfi | $115,965,989 | $41,321,214 | $307,909,694 | $7,997,654 |
| Other | ||||
| Repayment Of Debt | $-2,250,006,771 | $-3,341,686,597 | $-3,456,319,643 | $-8,888,059,923 |
| Issuance Of Debt | $4,257,418,026 | $1,787,475,758 | $297,246,155 | $2,727,200,150 |
| End Cash Position | $4,274,746,277 | $4,536,002,987 | $3,809,549,379 | $4,565,327,720 |
| Beginning Cash Position | $4,536,002,987 | $3,809,549,379 | $4,565,327,720 | $5,090,507,026 |
| Effect Of Exchange Rate Changes | $-25,325,906 | $-71,978,890 | $-131,961,298 | $202,607,245 |
| Changes In Cash | $-235,930,805 | $798,432,498 | $-623,817,043 | $-727,786,550 |
| Interest Paid Cff | $-905,067,890 | $-842,419,597 | $-1,021,033,878 | $-1,130,335,155 |
| Common Stock Payments | $-1,835,461,685 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $2,007,411,254 | $-1,554,210,838 | $-3,159,073,488 | $-6,160,859,773 |
| Net Short Term Debt Issuance | $1,235,637,605 | $-834,421,942 | $-443,869,819 | $1,360,934,190 |
| Short Term Debt Payments | $-383,887,411 | $-1,188,984,621 | $-443,869,819 | $0 |
| Short Term Debt Issuance | $1,619,525,016 | $354,562,678 | $0 | $1,360,934,190 |
| Net Long Term Debt Issuance | $771,773,650 | $-719,788,896 | $-2,715,203,669 | $-7,521,793,963 |
| Long Term Debt Payments | $-1,866,119,360 | $-2,152,701,976 | $-3,012,449,824 | $-8,888,059,923 |
| Long Term Debt Issuance | $2,637,893,010 | $1,432,913,080 | $297,246,155 | $1,366,265,960 |
| Interest Received Cfi | $205,273,130 | $183,946,051 | $153,288,376 | $85,308,314 |
| Net Investment Purchase And Sale | $14,662,366 | $27,991,790 | $95,971,853 | $1,332,942 |
| Net Business Purchase And Sale | $-2,184,692,594 | $1,823,465,203 | $387,886,238 | $-4,180,107,366 |
| Sale Of Business | $251,926,114 | $3,140,412,294 | $2,508,597,597 | $317,240,291 |
| Purchase Of Business | $-2,436,618,707 | $-1,316,947,091 | $-2,120,711,358 | $-4,497,347,658 |
| Net Intangibles Purchase And Sale | $-2,028,738,333 | $-1,935,432,365 | $-1,356,935,363 | $-1,224,974,066 |
| Sale Of Intangibles | $153,288,376 | $174,615,454 | $15,995,309 | $261,256,710 |
| Purchase Of Intangibles | $-2,182,026,709 | $-2,110,047,819 | $-1,372,930,672 | $-1,486,230,776 |
| Net PPE Purchase And Sale | $-1,764,815,738 | $-1,778,145,162 | $-1,714,163,926 | $-1,328,943,573 |
| Sale Of PPE | $31,990,618 | $86,641,256 | $37,322,387 | $194,609,590 |
| Purchase Of PPE | $-1,796,806,355 | $-1,864,786,418 | $-1,751,486,314 | $-1,523,553,163 |
| Taxes Refund Paid | $-1,602,196,765 | $-1,742,155,717 | $-1,770,147,507 | $-1,746,154,544 |
| Change In Working Capital | $-1,915,438,229 | $2,785,849,616 | $-485,191,034 | $359,894,448 |
| Change In Other Current Liabilities | $619,818,216 | $2,444,616,362 | $655,807,661 | $2,170,030,227 |
| Change In Other Current Assets | $-1,518,221,394 | $1,331,609,458 | $-609,154,677 | $-1,282,290,589 |
| Change In Payable | $631,814,698 | $-1,051,691,554 | $898,403,178 | $651,808,834 |
| Change In Inventory | $-186,611,936 | $-391,885,066 | $-565,167,578 | $-358,561,506 |
| Change In Receivables | $-1,462,237,813 | $453,200,416 | $-865,079,618 | $-821,092,518 |
| Other Non Cash Items | $757,111,283 | $530,511,075 | $626,482,928 | $466,529,840 |
| Stock Based Compensation | $498,520,458 | $458,532,186 | $409,213,317 | $461,198,070 |
| Deferred Tax | $1,482,231,949 | $701,127,702 | $1,007,704,454 | $942,390,277 |
| Depreciation And Amortization | $3,084,428,714 | $3,400,336,062 | $3,057,769,866 | $2,861,827,333 |
| Amortization Cash Flow | $1,676,841,539 | $1,938,098,250 | $1,615,526,189 | $1,447,575,446 |
| Depreciation | $1,407,587,174 | $1,462,237,813 | $1,442,243,677 | $1,414,251,886 |
| Gain Loss On Investment Securities | $-5,331,770 | $-13,329,424 | - | $-1,332,942 |
| Gain Loss On Sale Of PPE | $-65,314,178 | $-226,600,208 | $-15,995,309 | $-246,594,344 |
| Gain Loss On Sale Of Business | $11,996,482 | $6,664,712 | $-1,332,942 | $-47,985,926 |
| Net Income From Continuing Operations | $8,382,874,754 | $3,933,513,022 | $7,075,258,259 | $6,559,409,550 |
| Sale Of Investment | - | $27,991,790 | $95,971,853 | $1,332,942 |
Fetched: 2026-10-18